AR082645A1 - COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME - Google Patents
COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROMEInfo
- Publication number
- AR082645A1 AR082645A1 ARP110103104A AR082645A1 AR 082645 A1 AR082645 A1 AR 082645A1 AR P110103104 A ARP110103104 A AR P110103104A AR 082645 A1 AR082645 A1 AR 082645A1
- Authority
- AR
- Argentina
- Prior art keywords
- ezatiostat
- salt
- per day
- hydrochloride
- grams
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title 1
- XJDYQYNYISTAMO-GFDYFVENSA-N ethyl (2s)-2-amino-5-[[(2r)-3-benzylsulfanyl-1-[[(1r)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate;hydrochloride Chemical compound Cl.C([C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)C=1C=CC=CC=1)SCC1=CC=CC=C1 XJDYQYNYISTAMO-GFDYFVENSA-N 0.000 abstract 6
- GWEJFLVSOGNLSS-WPFOTENUSA-N ethyl (2s)-2-amino-5-[[(2r)-3-benzylsulfanyl-1-[[(1r)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate Chemical compound C([C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)C=1C=CC=CC=1)SCC1=CC=CC=C1 GWEJFLVSOGNLSS-WPFOTENUSA-N 0.000 abstract 5
- 229950003030 ezatiostat Drugs 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Regímenes de tratamiento específicos para tratar síndrome mielodisplásico.Reivindicación 1: El uso de una cantidad terapéuticamente eficaz de ezatiostat o una sal del mismo para la preparación de un medicamento oral para tratar un síndrome mielodisplásico, dicho ezatiostat o una sal del mismo es equivalente a hasta 2 gramos de ezatiostat clorhidrato por día durante al menos 2 semanas. Reivindicación 2: El uso de la reivindicación 1 donde el ezatiostat o una sal del mismo es ezatiostat clorhidrato. Reivindicación 3: El uso de la reivindicación 1, donde dicha cantidad terapéuticamente eficaz de ezatiostat clorhidrato es 2 gramos por día. Reivindicación 4: El uso de la reivindicación 3, donde el ezatiostat clorhidrato se administra en dos dosis separadas de 1 gramo por día. Reivindicación 5: El uso de la reivindicación 4, donde la segunda dosis se administra a un intervalo que va desde 6 hasta 14 horas después de la primera dosis. Reivindicación 10: Un método para tratar un síndrome mielodisplásico en un paciente cuyo método comprende administrar oralmente a dicho paciente una cantidad terapéuticamente eficaz de ezatiostat o una sal del mismo equivalente a hasta aproximadamente 2 gramos por día de ezatiostat clorhidrato durante al menos 2 semanas. Reivindicación 18: Una composición que comprende ezatiostat o una sal del mismo en una cantidad equivalente a hasta aproximadamente 2 gramos de ezatiostat clorhidrato por día durante al menos 2 semanas.Specific treatment regimens for treating myelodysplastic syndrome. Claim 1: The use of a therapeutically effective amount of ezatiostat or a salt thereof for the preparation of an oral medicament for treating a myelodysplastic syndrome, said ezatiostat or a salt thereof is equivalent to up to 2 grams of ezatiostat hydrochloride per day for at least 2 weeks. Claim 2: The use of claim 1 wherein the ezatiostat or a salt thereof is ezatiostat hydrochloride. Claim 3: The use of claim 1, wherein said therapeutically effective amount of ezatiostat hydrochloride is 2 grams per day. Claim 4: The use of claim 3, wherein the ezatiostat hydrochloride is administered in two separate doses of 1 gram per day. Claim 5: The use of claim 4, wherein the second dose is administered at an interval ranging from 6 to 14 hours after the first dose. Claim 10: A method of treating a myelodysplastic syndrome in a patient whose method comprises orally administering to said patient a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride for at least 2 weeks. Claim 18: A composition comprising ezatiostat or a salt thereof in an amount equivalent to up to about 2 grams of ezatiostat hydrochloride per day for at least 2 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110103104 AR082645A1 (en) | 2011-08-25 | 2011-08-25 | COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP110103104 AR082645A1 (en) | 2011-08-25 | 2011-08-25 | COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082645A1 true AR082645A1 (en) | 2012-12-19 |
Family
ID=47562094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103104 AR082645A1 (en) | 2011-08-25 | 2011-08-25 | COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR082645A1 (en) |
-
2011
- 2011-08-25 AR ARP110103104 patent/AR082645A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| AR090885A1 (en) | USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| PE20142319A1 (en) | MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE | |
| BR112015029512A2 (en) | pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
| EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
| EA201590166A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS | |
| UA107578C2 (en) | COMBINED DIABETES THERAPY | |
| EA201491285A1 (en) | IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID | |
| BR112015029401A8 (en) | pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination | |
| BR112015010396A2 (en) | combination therapy | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| ES2570401T3 (en) | Methods of treatment using single doses of oritavancin | |
| HRP20192189T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| AR088204A1 (en) | MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST | |
| AR091724A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION | |
| BR112014004339A2 (en) | oral suspension | |
| MX2018005298A (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| AR082645A1 (en) | COMPOSITIONS AND METHODS TO TREAT MYELODISPLASIC SYNDROME | |
| MX2010006310A (en) | O-desmethyl-venlafaxine for treating major depressive disorder. | |
| AR094287A1 (en) | METHODS AND COMPOSITIONS FOR OXIBUTININE ADMINISTRATION | |
| RU2013126798A (en) | COMBINED THERAPY BY DEXAMETASONE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |